Fig. 2: New prognostic biomarkers of CLL clinical evolution.

a–b Kaplan–Meier plots indicating the association between mutations in the TP53 pathway and time to treatment with and without TP53 mutated cases (Fig. 2a, b, respectively). The red line indicates patients without mutation in this pathway, whereas the green and blue lines indicate patients with one or more than one mutation, respectively. c–d Kaplan–Meier plots indicating the association of mutations in the 3′ UTR and flanking region of IGKC with time to treatment. In Fig. 2c the red line indicates those patients without mutations in this region and the blue line indicate mutated cases. Similarly, in Fig. 2d the blue line indicates IGHV mutated cases with mutation in IGKC, the red line indicates IGHV mutated cases without IGKC mutation, the purple line indicates IGHV unmutated cases with IGKC mutation and the green line indicates those patients with both unmutated IGHV and IGKC